Arama Sonuçları - David B. Solit

Sonuçları Daraltın
  1. 1
    Towards a Unified Model of RAF Inhibitor Resistance

    Towards a Unified Model of RAF Inhibitor Resistance Yazar: David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    KRAS and BRAF: drug targets and predictive biomarkers

    KRAS and BRAF: drug targets and predictive biomarkers Yazar: Efsevia Vakiani, David B. Solit

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response Yazar: Christine A. Pratilas, David B. Solit

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Targeting Oncogenic BRAF in Human Cancer

    Targeting Oncogenic BRAF in Human Cancer Yazar: Christine A. Pratilas, Feng Xing, David B. Solit

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged Yazar: Paul B. Chapman, David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    ERK Pathway Inhibitors: How Low Should We Go?

    ERK Pathway Inhibitors: How Low Should We Go? Yazar: Moriah H. Nissan, Neal Rosen, David B. Solit

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Trametinib in Histiocytic Sarcoma with an Activating <i>MAP2K1</i> (MEK1) Mutation

    Trametinib in Histiocytic Sarcoma with an Activating <i>MAP2K1</i> (MEK1) Mutation Yazar: Mrinal M. Gounder, David B. Solit, William D. Tap

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Carta
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

    Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 Yazar: Andrea Basso, David B. Solit, Pamela N. Münster, Neal Rosen

    Baskı/Yayın Bilgisi 2002
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells

    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells Yazar: Gil Redelman‐Sidi, Gopa Iyer, David B. Solit, Michael S. Glickman

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Yazar: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Editorial
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Clinical tumour sequencing for precision oncology: time for a universal strategy

    Clinical tumour sequencing for precision oncology: time for a universal strategy Yazar: Michael L. Cheng, Michael F. Berger, David M. Hyman, David B. Solit

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function

    Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function Yazar: Andrea Basso, David B. Solit, Gabriela Chiosis, Banabihari Giri, Philip N. Tsichlis, Neal Rosen

    Baskı/Yayın Bilgisi 2002
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

    V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors Yazar: Olivera M. Grbovic, Andrea Basso, Ayana Sawai, Q. Ye, Philip Friedlander, David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2005
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway Yazar: Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2009
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

    The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells Yazar: Qing‐Bai She, David B. Solit, Qing Ye, Kathryn E. O’Reilly, Jose Lobo, Neal Rosen

    Baskı/Yayın Bilgisi 2005
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors

    Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors Yazar: Seungchan Yang, Shimian Qu, Marianela Perez-Tores, Ayana Sawai, Neal Rosen, David B. Solit, Carlos L. Arteaga

    Baskı/Yayın Bilgisi 2006
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling Yazar: Ensar Halilovic, Qing‐Bai She, Qing Ye, Raymond Pagliarini, William R. Sellers, David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

    Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel Yazar: David B. Solit, Yuhong She, Jose Lobo, Mark G. Kris, Howard I. Scher, Neal Rosen, Frank Sirotnak

    Baskı/Yayın Bilgisi 2005
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors Yazar: Qing‐Bai She, Ensar Halilovic, Qing Ye, Zhen Wei, Senji Shirasawa, Takehiko Sasazuki, David B. Solit, Neal Rosen

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials Yazar: David M. Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul Sabbatini, José Baselga, Michael F. Berger, Marc Ladanyi

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: